Dr Reddy's launches osteoporosis injection in US - Business Standard

Prashanth Reddy Chintala  |  Hyderabad  April 4, 2013 Last Updated at 12:53 IST The company's scrip was trading on BSE at Rs 1,888 on Thursday, up 2.8% from previous close Hyderabad-based pharmaceutical major Dr Reddy's Laboratories (DRL) has launched zoledronic acid injection in the US market following approval by the United States Food & Drug Administration (USFDA). The medicine, used to treat osteoporosis in women after menopause, is a therapeutic equivalent generic version of Reclast (zoledronic acid) injection, DRL stated in a press release on Thursday. The Reclast brand had total US sales of approximately $ 355 million for the most recent twelve months ending February 2013, according to IMS Health.   DRL's zoledronic acid injection is available in a single use vial for intravenous infusion. The company's scrip was trading on BSE at Rs 1,888 on Thursday, up 2.9 per cent over the previous close of Rs 1,834.85. via Business - Google News http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNG5C85x-9ZRRBjGKpnSS5_wLmLr4w&url=http://www.business-standard.com/article/companies/dr-reddy-s-launches-osteoporosis-injection-in-us-113040400124_1.html

Put the internet to work for you. via Personal Recipe 2910127